Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 Genitourinary Cancers Symposium /
6-factor prognostic model for patients with advanced urothelial carcinoma

8th - 10th Feb 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.02.18
Views: 653
Rating:

Dr Gregory Pond - McMaster University, Hamilton, Ontario

Dr Pond speaks with ecancer at the 2018 ASCO Genitourinary Cancers Symposium about a new 6-factor prognostic model for patients with advanced urothelial carcinoma receiving post-platinum atezolizumab.

The model is based on two previous clinical trials using atezolizumab.

Six factors were deduced which were prognostic for survival.

The adverse risk factors for each of the six were identified (risk stratification) and quantified for each patients.

This was then evaluated against the second previous clinical trail dataset.

He found that those with 4 or more risk factors had a median survival of less than 3 months - which means those patients may not benefit from immunotherapy, an important factor to identify. 

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation